
## SÃ, ren Lund Kristensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7065797/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 776-785.	5.5	961
2	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 653-662.	5.5	437
3	Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention. Circulation, 2012, 126, 1185-1193.	1.6	381
4	Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After MyocardialÂInfarction and Coronary Intervention. Journal of the American College of Cardiology, 2013, 62, 981-989.	1.2	313
5	Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	260
6	SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia, 2016, 59, 1333-1339.	2.9	254
7	Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study. PLoS ONE, 2013, 8, e56944.	1.1	182
8	Cardiovascular outcomes and systemic antiâ€inflammatory drugs in patients with severe psoriasis: 5â€year followâ€up of a Danish nationwide cohort. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1128-1134.	1.3	164
9	Cardiovascular disease event rates in patients with severe psoriasis treated with systemic antiâ€inflammatory drugs: a <scp>D</scp> anish realâ€world cohort study. Journal of Internal Medicine, 2013, 273, 197-204.	2.7	155
10	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2017, 135, 724-735.	1.6	153
11	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation, 2018, 138, 2774-2786.	1.6	139
12	Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 2016, 37, 3167-3174.	1.0	114
13	Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. Europace, 2014, 16, 477-484.	0.7	107
14	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541.	1.6	96
15	Dementiaâ€related adverse events in <scp>PARADIGMâ€HF</scp> and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137.	2.9	95
16	Association of Carpal Tunnel Syndrome With Amyloidosis, HeartÂFailure, and Adverse Cardiovascular Outcomes. Journal of the American College of Cardiology, 2019, 74, 15-23.	1.2	77
17	Psoriasis and risk of heart failure: a nationwide cohort study. European Journal of Heart Failure, 2014, 16, 743-748.	2.9	75
18	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Election Fraction. Circulation, 2015, 131, 43-53.	1.6	75

## SÃ, ren Lund Kristensen

#	Article	IF	CITATIONS
19	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	1.9	75
20	The New Pooled Cohort Equations Risk Calculator. Canadian Journal of Cardiology, 2015, 31, 613-619.	0.8	67
21	Psoriasis and New-Onset Diabetes. Diabetes Care, 2013, 36, 2402-2407.	4.3	65
22	Accuracy of the ICD-10 discharge diagnosis for syncope. Europace, 2013, 15, 595-600.	0.7	64
23	Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure. Circulation: Heart Failure, 2014, 7, 717-722.	1.6	63
24	Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. Journal of the American College of Cardiology, 2020, 76, 767-777.	1.2	61
25	Diabetic cardiomyopathy. Heart, 2019, 105, 337-345.	1.2	60
26	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovascular Drugs and Therapy, 2017, 31, 545-549.	1.3	55
27	The prognostic value of troponin T and Nâ€ŧerminal pro Bâ€ŧype natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.	2.9	54
28	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	1.6	53
29	Readmission and death in patients admitted with newâ€onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 2020, 22, 1777-1785.	2.9	53
30	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 974-984.	2.9	52
31	Return to the Workforce After First Hospitalization for Heart Failure. Circulation, 2016, 134, 999-1009.	1.6	50
32	Pharmacological Undertreatment of Coronary Risk Factors in Patients with Psoriasis: Observational Study of the Danish Nationwide Registries. PLoS ONE, 2012, 7, e36342.	1.1	48
33	Atrial fibrillation and risk of stroke: a nationwide cohort study. Europace, 2016, 18, 1689-1697.	0.7	45
34	Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. Journal of the American College of Cardiology, 2021, 77, 1717-1727.	1.2	44
35	Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: followâ€up of 4.5 million Danish adults. Journal of Internal Medicine, 2014, 276, 659-666.	2.7	43
36	Long-Term Outcome in Levothyroxine Treated Patients With Subclinical Hypothyroidism and Concomitant Heart Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4170-4177.	1.8	38

#	Article	IF	CITATIONS
37	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. Diabetes Care, 2018, 41, 1285-1291.	4.3	38
38	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 169-176.	2.9	36
39	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522.	2.9	35
40	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41.	1.2	32
41	Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509.	2.9	30
42	Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study. Lupus, 2017, 26, 1435-1439.	0.8	29
43	Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit. JACC: Heart Failure, 2019, 7, 717-724.	1.9	29
44	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Canadian Journal of Cardiology, 2017, 33, 1472-1477.	0.8	28
45	Burden and Causes of HospitalÂAdmissions in HeartÂFailure During the Last Year of Life. JACC: Heart Failure, 2019, 7, 561-570.	1.9	28
46	Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006260.	0.9	28
47	Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. Cardiovascular Diabetology, 2019, 18, 79.	2.7	26
48	Antithrombotic Treatment in Patients With Heart Failure and Associated Atrial Fibrillation and Vascular Disease. Journal of the American College of Cardiology, 2014, 63, 2689-2698.	1.2	25
49	One‥ear Mortality After Intensification of Outpatient Diuretic Therapy. Journal of the American Heart Association, 2020, 9, e016010.	1.6	25
50	Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102382.	1.8	22
51	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro–B-Type Natriuretic Peptide Level asÂPredictors of Outcomes in PatientsÂWithÂHeart Failure and PreservedAEjectionÂFraction. JACC: Heart Failure, 2015, 3, 478-486.	1.9	21
52	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circulation: Heart Failure, 2019, 12, e005766.	1.6	21
53	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). American Heart lournal. 2021. 231. 137-146.	1.2	21
54	Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation?. Annals of the Rheumatic Diseases, 2015, 74, 321-322.	0.5	20

#	Article	IF	CITATIONS
55	Return to the workforce following coronary artery bypass grafting: A Danish nationwide cohort study. International Journal of Cardiology, 2018, 251, 15-21.	0.8	20
56	Prognosis After First-Time Myocardial Infarction in Patients With Inflammatory Bowel Disease According to Disease Activity. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 857-862.	0.9	18
57	Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives. American Journal of Cardiovascular Drugs, 2016, 16, 1-8.	1.0	18
58	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <scp>ATMOSPHERE</scp> trial. European Journal of Heart Failure, 2018, 20, 136-147.	2.9	18
59	Long-Term Outcome in Patients With Heart Failure Treated With Levothyroxine: An Observational Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1725-1734.	1.8	18
60	Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovascular Diabetology, 2020, 19, 107.	2.7	18
61	Use of nonsteroidal antiâ€inflammatory drugs prior to chronic renal replacement therapy initiation: a nationwide study. Pharmacoepidemiology and Drug Safety, 2012, 21, 428-434.	0.9	17
62	The Viability of Perilabyrinthine Osteocytes: A Quantitative Study Using Bulk‣tained Undecalcified Human Temporal Bones. Anatomical Record, 2012, 295, 1101-1108.	0.8	17
63	Microvascular complications in diabetes patients with heart failure and reduced ejection fraction—insights from the Betaâ€blocker Evaluation of Survival Trial. European Journal of Heart Failure, 2018, 20, 1549-1556.	2.9	17
64	<p>Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers</p> . Clinical Epidemiology, 2020, Volume 12, 589-594.	1.5	17
65	Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. European Journal of Heart Failure, 2018, 20, 240-247.	2.9	16
66	Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e022638.	1.6	16
67	Return to the workforce following infective endocarditis—A nationwide cohort study. American Heart Journal, 2018, 195, 130-138.	1.2	15
68	Syncope and Its Impact on Occupational Accidents and Employment. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	14
69	Prevalence and incidence of intraâ€ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGMâ€HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	2.9	14
70	Long-term Risk of Death and Hospitalization in Patients With Heart Failure and Takotsubo Syndrome: Insights From a Nationwide Cohort. Journal of Cardiac Failure, 2022, 28, 1534-1544.	0.7	14
71	Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. International Journal of Cardiology, 2013, 168, 832-837.	0.8	13
72	Low-Dose Aspirin in Heart Failure NotÂComplicatedÂby Atrial Fibrillation. JACC: Heart Failure, 2018, 6, 156-167.	1.9	11

#	Article	IF	CITATIONS
73	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2019, 108, 868-877.	1.5	11
74	Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis. Journal of the American College of Cardiology, 2020, 76, 2623-2631.	1.2	11
75	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	1.5	10
76	Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study. Circulation: Heart Failure, 2021, 14, e008662.	1.6	10
77	Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. BMC Neurology, 2015, 15, 225.	0.8	9
78	The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace, 2019, 21, 1203-1210.	0.7	9
79	Nursing Home Admission and Initiation of Domiciliary Care Following Infective Endocarditis. Global Heart, 2020, 14, 41.	0.9	9
80	Stent Thrombosis is the Primary Cause of ST-Segment Elevation Myocardial Infarction following Coronary Stent Implantation: A Five Year Follow-Up of the SORT OUT II Study. PLoS ONE, 2014, 9, e113399.	1.1	8
81	Risk of stroke subsequent to infective endocarditis: A nationwide study. American Heart Journal, 2019, 212, 144-151.	1.2	7
82	Quality of life and the associated risk of all-cause mortality in nonischemic heart failure. International Journal of Cardiology, 2020, 305, 92-98.	0.8	7
83	Benefit of Clopidogrel Therapy in Patients With Myocardial Infarction and Chronic Kidney Disease—A Danish Nationâ€Wide Cohort Study. Journal of the American Heart Association, 2014, 3, .	1.6	6
84	Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity. International Journal of Cardiology, 2020, 305, 106-112.	0.8	6
85	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and endâ€stage renal disease. European Journal of Heart Failure, 2020, 22, 813-820.	2.9	6
86	Long-term prognosis following hospitalization for acute myocarditis – a matched nationwide cohort study. Scandinavian Cardiovascular Journal, 2021, 55, 264-269.	0.4	6
87	Five-year risk of heart failure and death following myocardial infarction with cardiogenic shock: a nationwide cohort study. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 40-49.	0.4	5
88	Rate of Heart Failure Following Atrial Fibrillation According to Presence of Family History of Dilated Cardiomyopathy or Heart Failure: A Nationwide Study. Journal of the American Heart Association, 2021, 10, e021286.	1.6	4
89	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. JACC: Heart Failure, 2018, 6, 41-48.	1.9	3
90	Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation. Open Heart, 2020, 7. e001369.	0.9	3

#	Article	IF	CITATIONS
91	The effect of sodiumâ€glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies. Diabetic Medicine, 2021, 38, e14600.	1.2	3
92	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 2021, 16, e0255364.	1.1	3
93	Nursing Home Admission and Initiation of Domiciliary Care After Ischemic Stroke – The Importance of Time to Thrombolysis. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105916.	0.7	3
94	Long-term Risk of Heart Failure and Other Adverse Cardiovascular Outcomes in Granulomatosis With Polyangiitis: A Nationwide Cohort Study. Journal of Rheumatology, 2022, 49, 291-298.	1.0	3
95	Response to Letter Regarding Article, "Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study― Circulation, 2013, 127, e585.	1.6	2
96	Longâ€Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. Journal of the American Heart Association, 2021, 10, e021310.	1.6	2
97	Return to work after acute myocardial infarction with cardiogenic shock: a Danish nationwide cohort study. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 397-406.	0.4	2
98	Individualizing surgical revascularization in patients with ischaemic heart failure — a further dive into STICHES. European Journal of Heart Failure, 2019, 21, 382-384.	2.9	1
99	Diagnosing heart failure with preserved ejection fraction–Âwhat's the score?. European Journal of Heart Failure, 2020, 22, 425-427.	2.9	1
100	Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e024402.	1.6	1
101	Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. Clinical Research in Cardiology, 2022, , 1.	1.5	1
102	Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine. BMC Cardiovascular Disorders, 2021, 21, 622.	0.7	1
103	Reply. Journal of the American College of Cardiology, 2014, 64, 231-232.	1.2	0
104	Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. Pharmacoepidemiology and Drug Safety, 2014, 23, 1281-1287.	0.9	0
105	RETURN TO WORK FOLLOWING CORONARY ARTERY BYPASS GRAFTING: A NATIONWIDE STUDY. Journal of the American College of Cardiology, 2017, 69, 115.	1.2	0
106	Patterns of unplanned readmissions after heart failure hospitalization: novel longitudinal perspectives from <scp>Australia</scp> and <scp>New Zealand</scp> . European Journal of Heart Failure, 2021, 23, 41-42.	2.9	0
107	The association of prior carpal tunnel syndrome surgery with adverse cardiovascular outcomes and long-term mortality after aortic valve replacement. IJC Heart and Vasculature, 2021, 33, 100741.	0.6	0
108	The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes. Clinical Research in Cardiology, 2022, 111, 460-468.	1.5	0